Eyenovia, Inc. Common Stock
EYEN US30234E1047
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Rowe Michael M CEO |
0.52 USD |
27,071 Bought |
14,077 USD |
28/08/2024 | 28/08/2024 |
| Rowe Michael M CEO |
0.57 USD |
50,000 Bought |
28,500 USD |
26/08/2024 | 26/08/2024 |
| Grant Stuart M. O |
0.66 USD |
1,515,151 Bought |
1,000,000 USD |
02/07/2024 | 02/07/2024 |
| Grant Stuart M. O |
0.98 USD |
100,000 Bought |
98,000 USD |
28/03/2024 | 28/03/2024 |
| Grant Stuart M. O |
1.23 USD |
50,000 Bought |
61,500 USD |
19/03/2024 | 19/03/2024 |
| Grant Stuart M. O |
1.58 USD |
10,717 Bought |
16,911 USD |
08/03/2024 | 08/03/2024 |
| Rowe Michael M CEO |
1.36 USD |
4,890 Bought |
6,650 USD |
04/12/2023 | 04/12/2023 |